Related Experiment Video
Updated: Jul 7, 2025
A Modified Method for Heterotopic Mouse Heart Transplantion
Published on: June 23, 2014
Protein Phosphatase 2A Activation Promotes Heart Transplant Acceptance in Mice
Xianming Zhou1,2, Qian Xu1,3, Wangzi Li2
1Cardiology Division, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Background:
Although heart transplantation is the definitive treatment for heart failure in eligible patients, both acute and chronic transplant rejection frequently occur. Protein phosphatase 2A (PP2A) activity is critical in maintaining tissue and organ homeostasis. In this study, we evaluated the effect of a novel class of small molecule activators of PP2A (SMAPs) on allograft rejection in a mouse heterotopic heart transplantation model.
Methods:
Recipient mice were administered with DT-061 (a pharmaceutically optimized SMAP) or vehicle by oral gavage beginning 1 d after transplantation. Histological and immunofluorescence analyses were performed to examine allograft rejection. Regulatory T cells (Treg) from recipient spleens were subjected to flow cytometry and RNA sequencing analysis. Finally, the effect of DT-061 on smooth muscle cells (SMCs) migration and proliferation was assessed.
Results:
DT-061 treatment prolonged cardiac allograft survival. SMAPs effectively suppressed the inflammatory immune response while increasing Treg population in the allografts, findings corroborated by functional analysis of RNA sequencing data derived from Treg of treated splenic tissues. Importantly, SMAPs extended immunosuppressive agent cytotoxic T lymphocyte-associated antigen-4-Ig-induced cardiac transplantation tolerance and allograft survival. SMAPs also strongly mitigated cardiac allograft vasculopathy as evidenced by a marked reduction of neointimal hyperplasia and SMC proliferation. Finally, our in vitro studies implicate suppression of MEK/ERK pathways as a unifying mechanism for the effect of PP2A modulation in Treg and SMCs.
Conclusions:
PP2A activation prevents cardiac rejection and prolongs allograft survival in a murine model. Our findings highlight the potential of PP2A activation in improving alloengraftment in heart transplantation.
Insights
Small molecule activators of Protein Phosphatase 2A (PP2A) significantly prolonged heart transplant survival in mice. These activators suppressed immune responses and reduced vasculopathy, offering a promising new strategy for preventing organ transplant rejection.
Area of Science:
- Immunology
- Pharmacology
- Transplantation Science
Background:
- Heart transplantation is a key treatment for heart failure, but acute and chronic rejection remain significant challenges.
- Protein phosphatase 2A (PP2A) plays a vital role in maintaining tissue homeostasis.
- Novel small molecule activators of PP2A (SMAPs) were investigated for their potential to mitigate transplant rejection.
Purpose of the Study:
- To evaluate the efficacy of a novel small molecule activator of PP2A (SMAP), DT-061, in preventing cardiac allograft rejection.
- To investigate the immunomodulatory effects of SMAPs on regulatory T cells (Tregs) and smooth muscle cells (SMCs).
- To explore the underlying molecular mechanisms of SMAP action in a murine heart transplantation model.
Main Methods:
- A heterotopic heart transplantation mouse model was utilized.
- Recipient mice received DT-061 or vehicle orally post-transplantation.
- Histological, immunofluorescence, flow cytometry, and RNA sequencing analyses were performed on allografts and regulatory T cells.
Main Results:
- DT-061 treatment significantly prolonged cardiac allograft survival.
- SMAPs suppressed inflammatory responses and increased Treg populations, confirmed by RNA sequencing.
- SMAPs reduced cardiac allograft vasculopathy by inhibiting neointimal hyperplasia and SMC proliferation.
- In vitro studies suggested MEK/ERK pathway suppression as a mechanism for PP2A modulation in Tregs and SMCs.
Conclusions:
- PP2A activation by SMAPs effectively prevents cardiac rejection and extends allograft survival in a murine model.
- These findings underscore the therapeutic potential of PP2A activation for improving outcomes in heart transplantation.
- SMAPs represent a promising new class of agents for enhancing alloengraftment and preventing transplant rejection.
